Torrent Pharma launches Adfrar – biosimilar adalimumab in India

January 12, 2016 6:55 AM

Torrent-Pharma-biosimilarnews-logo

Torrent Pharma enters 2016 by announcing the launch of biosimilar adalimumab in India under the brand name ‘Adfrar’.

Adalimumab is the most preferred therapy for the treatment of auto immune disorders and has wide applications like Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis and Plaque Psoriasis. Adalimumab is the largest selling drug across the globe (innovator brand Humira has sales of 15 billion USD). Torrent’s brand ‘Adfrar’ will be the second biosimilar adalimumab in the world.

Autoimmune disorders are growing ailments and Monoclonal Antibodies are becoming mainstay of treatment, therefore launch of ‘Adfrar’ is a significant step towards fortifying its presence in MAb market.

Biosimilar rituximab – ‘Toritz RA’ is already launched in Rheumatology segment and now with launch of biosimilar adalimumab – ‘Adfrar’, Torrent presence in this segment will get a major fillip, making it a significant player in this super speciality.

‘Adfrar’ will be available as Pre Filled Syringe of 40mg. Torrent will promote this biosimilar to Rheumatologists, Gastroenterologists and Dermatologists pan India.

Source: Torrent Pharma press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!